(Circulation. 2000;102:I-166.)
© 2000 American Heart Association, Inc.
ECC Guidelines |
| Return of Spontaneous Circulation After a No-Flow Cardiac Arrest |
|---|
|
|
|---|
Multiple pathogenic factors contribute to the postresuscitation syndrome:
After restoration of circulation, 4 phases of the postresuscitation syndrome occur, dependent on the degree and duration of organ ischemia.2
The principal objective of the postresuscitation phase is the complete reestablishment of regional organ and tissue perfusion. Simple restoration of blood pressure alone and improvement in tissue gas exchange do not necessarily improve survival. Notably, these end points fail to indicate appropriate resuscitation of peripheral organ systems and their blood supply, particularly the splanchnic and renal circulation, which contribute importantly to MODS after hypoxic-ischemic arrest.3 4 5
In most cases the acidemia associated with cardiac arrest improves spontaneously when adequate ventilation and perfusion have been restored. Persistent unrecognized splanchnic hypoperfusion will be identified only with specific monitoring and requires targeted therapy.6 7 In addition to invasive hemodynamic monitoring with pulmonary artery catheters, which remains controversial,8 9 10 splanchnic resuscitation should be directed by quantitative gastric tonometric measurement of the systemic:gastric mucosal PCO2 gradient. Targeted correction of systemic:gastric mucosal PCO2 gradient may be an important adjunct to invasive hemodynamic monitoring in the ICU but is presently unproven and is not widely available.11 11A 12 The purpose is to maximize splanchnic perfusion in the early postresuscitation phase and avoid progression to MODS.
These 2000 ACLS guidelines incorporate our evolving understanding of the hemodynamic abnormalities encountered in patients who survive resuscitation. Recommendations are generally based on data derived from studies of posttraumatic and medical SIRS. Very few clinical randomized studies have been published dealing specifically with hemodynamic support after neurocerebral resuscitation for cardiac arrest.
The immediate goals of postresuscitation care are to
Immediately after resuscitation, patients may exhibit a wide spectrum of physiological states. Patients may recover fully with normal hemodynamic and cerebral function. At the other end of the spectrum, patients remain comatose with cardiorespiratory abnormalities. All patients require careful, repeated assessments to establish the status of their cardiovascular, respiratory, and neurological systems. Clinicians should identify complications, such as rib fracture, hemopneumothorax, pericardial tamponade, intra-abdominal trauma, and misplaced tracheal tube.
| Optimal Response to Resuscitation |
|---|
|
|
|---|
Clinicians should consider the precipitating cause of the cardiac arrest, particularly an AMI, electrolyte disturbances, or primary arrhythmias. If an antiarrhythmic agent was used successfully during the resuscitation, administer a continuous infusion of that agent. If hemodynamically significant bradycardia is present, initiate therapy as described in the guidelines section on bradycardia. Consider fibrinolytic therapy for patients who survive resuscitations of short duration and with minimal trauma with evidence of acute ST-segment elevation MI on their postresuscitation 12-lead ECG and who have no contraindications to fibrinolytic therapy. Patients with contraindications to fibrinolytic therapy should be considered for urgent coronary angiography and appropriate intervention.14 Consider the patients neurological status, but coma should not preclude indicated interventions. Acute coronary syndromes must be evaluated with serial ECG and cardiac markers in all patients. Assess the hemodynamic status, vital signs, and urine output.
Perform laboratory investigations, including a 12-lead ECG; portable chest x-ray; determination of arterial blood gases, electrolyte, glucose, serum creatinine, blood urea nitrogen, magnesium, and calcium levels; and other appropriate chemical analyses. Treat aberrations in potassium, magnesium, calcium, and sodium levels aggressively. In candidates for fibrinolytic therapy, perform arterial punctures only if less invasive assessments of oxygenation (pulse oximetry), ventilation (expired CO2), and acid-base status (venous sample) are unavailable and clinically relevant information is unavailable by other noninvasive methods. Prearrest status must be reviewed carefully, particularly if the patient was receiving drug therapy. After completion of these steps, transfer the patient with oxygen and ECG monitoring to a special care unit for observation, continuous monitoring, and further therapeutic intervention. Resuscitation equipment and an adequate number of trained personnel must accompany the patient in transport.
| Temperature Regulation |
|---|
|
|
|---|
Hypothermia
Hypothermia, in contrast, is an effective method to suppress
cerebral metabolic activity. Although previously used
widely during cardiovascular surgery, hypothermia has
significant detrimental effects that might adversely affect the
postcardiac arrest patient, including increased blood viscosity,
decreased cardiac output, and increased susceptibility to infection.
Many reports indicate benefit after brain ischemia, although
some document detrimental effects or lack of improvement. Recent
evidence indicates that mild levels of hypothermia (eg, 34°C
[93°F]) are effective in mitigating postischemic brain
damage without detrimental side effects.15 16 17 18 19 20 21 In the
normal brain, a 7% reduction in the cerebral metabolic
rate occurs with every 1°C (2°F) reduction in brain
temperature.22
After cardiac arrest, hypermetabolism may cause fever and disrupt the balance between cerebral oxygen supply and demand. This suggests a possible clinical role for induced mild hypothermia.17
Interest in hypothermia as a treatment modality for brain injury was rekindled in the late 1980s and early 1990s when experiments performed in carefully controlled rodent models of brain ischemia (by cerebral vascular occlusion techniques) and dog experiments of cardiac arrest showed that even mild intraischemic hypothermia could be neuroprotective. The ability to improve neurological outcomes by cooling brain-injured humans quickly and safely was demonstrated by Marion et al17 in a randomized, controlled trial comparing the effects of moderate hypothermia (32°C to 33°C [89.5°F to 91.5°F] for 24 hours) with normothermia in 82 patients with severe closed-head injuries. As of early 2000 there was an active, randomized European multicenter trial of resuscitative hypothermia after cardiac arrest. The investigators anticipate an enrollment of 500 patients.
Side effects of hypothermia include coagulopathy, cardiac dysrhythmias,
impaired cardiac function, and increased susceptibility to infection.
The prevalence and severity of these side effects is proportional to
the depth and duration of hypothermia. Investigations inducing mild to
moderate hypothermia in humans after cardiac arrest (minimum
temperature
32°C [89.5°F]) for 24 to 36 hours have reported
hypothermia-related side effects.
In summary, hemodynamically stable patients who develop a mild degree of hypothermia (>33°C [91.5°F]) spontaneously after cardiac arrest should not be actively warmed. Mild hypothermia may be beneficial to neurological outcome and is likely to be well tolerated (Class IIb). However, hypothermia should not be induced actively after resuscitation from cardiac arrest (Class Indeterminate).
Hyperthermia
There are many studies in animal models of brain injury that show
exacerbation of injury if body/brain temperature is increased during
(intraischemic) or after cardiac arrest. Moreover, several
studies have documented worse neurological outcome in humans who have
fever after ischemic brain injury. Closely monitor temperature
after resuscitation from cardiac arrest, and treat fever aggressively
(Class IIa).
| Single- or Multiple-Organ System Failure: Requires Total or Near-Total Support |
|---|
|
|
|---|
During transportation of the patient to a critical care unit, mechanical ventilation and oxygenation must be maintained along with ECG monitoring. Assessment of circulatory status in transport with physical palpation of carotid or femoral pulses, continuous intra-arterial pressure monitoring, or pulse oximetry will allow for immediate initiation of CPR should another arrest occur. Equipment and personnel to accomplish immediate defibrillation and drug therapy must accompany the patient in transport.
Respiratory System
After ROSC, patients may exhibit various degrees of respiratory
dysfunction. Some patients will remain dependent on mechanical
ventilation and will need supplementary oxygen. Perform a complete
clinical examination and review the chest x-ray. Pay special attention
to potential complications of resuscitation, such as pneumothorax and
misplacement of the tracheal tube. The level of mechanical ventilatory
support is determined by the blood gas values, respiratory rate, and
perceived work of breathing. As spontaneous ventilation becomes more
efficient, the level of respiratory support can be decreased until
respiration is entirely spontaneous (decreasing intermittent mandatory
ventilation rates). If high oxygen concentrations are needed, it is
important to establish whether the cause is pulmonary or
cardiac dysfunction. Positive end-expiratory pressure (PEEP) may be
helpful in the patient with pulmonary dysfunction complicated
by left ventricular failure if the patient is
hemodynamically stable. If cardiac dysfunction is
present, support of the failing myocardium is
important. Adjust inspired oxygen concentration, PEEP, and minute
ventilation based on sequential arterial blood gas
analyses and/or noninvasive monitoring, such as pulse oximetry
and capnography. To facilitate repeated arterial
blood sampling, an arterial cannula may be necessary. The
systemic blood pressure can also be accurately and continuously
monitored from this arterial line.
Ventilatory Parameters
Recent evidence supports the theory that sustained hypocapnea (low
PCO2) may worsen cerebral
ischemia.23 24 25 After cardiac arrest, restoration
of blood flow results in an initial hyperemic blood flow
response lasting 10 to 30 minutes, which is followed by a more
prolonged period of low blood flow. During this period of delayed
hypoperfusion a mismatch between blood flow (oxygen delivery) and
oxygen metabolism may occur. If the patient is
hyperventilated at this stage, the additional cerebral vasoconstriction
resulting from a low PCO2 may further
decrease cerebral blood flow and worsen cerebral ischemia.
There is no evidence that hyperventilation protects vital organs from
further ischemic damage after cardiac arrest. The potential
risk for further brain ischemia is real, and hyperventilation
after cardiac arrest should be avoided. Safar et al26 also
showed indirectly that hyperventilation results in worse neurological
outcome. After cardiac arrest, dogs treated with mild hypothermia
enhanced by hypertension and ventilated to normocarbia had improved
outcome with this clinical management.
Hyperventilation may generate airway pressures and auto-PEEP, leading to an increase in cerebral venous and intracranial pressures.27 28 The increase in cerebral vascular pressure results in a decreased cerebral blood flow and a further worsening of brain ischemia. This mechanism is independent of the effects of PCO2 or pH on cerebral vessel reactivity.
In summary, after either cardiac arrest or head trauma, ventilate the comatose patient to achieve normocarbia (Class IIa). Routine hyperventilation may be detrimental and should be avoided (Class III). In specific situations hyperventilation to achieve hypocarbia may be beneficial. Treat cerebral herniation syndrome with hyperventilation (Class IIa). Hyperventilation may also have a role when pulmonary hypertension is the cause of arrest (Class IIa). With restoration of cardiac output, metabolic acidosis usually corrects over time, and hyperventilation should not be used as a primary treatment modality. The use of buffer therapy is also not indicated and should be used for specific indications only (see above).29 30
Cardiovascular System
Evaluation must include a complete vascular examination and review
of serial vital signs and urine output. Compare a 12-lead ECG with
previous tracings if available. Assess the chest x-ray; serum
electrolyte levels, including calcium and magnesium; and cardiac marker
levels. Review current and previous drug therapy. Serum cardiac marker
levels may be elevated because of resuscitative efforts alone as global
ischemia occurs during arrested or low-flow states. If the
patients condition is hemodynamically unstable,
assess both circulating fluid volume and ventricular
function. Avoid even mild hypotension because it can impair recovery of
cerebral function. Noninvasive assessment of blood pressure may be
inaccurate in patients with low cardiac output and
peripheral vasoconstriction. Intra-arterial
assessment of blood pressure is usually more accurate in these patients
and allows better titration of potentially dangerous
catecholamine infusions. In the presence of severe
vasoconstriction, blood pressure measurement from the radial artery may
be inaccurate, and a femoral artery catheter may be considered.
In the critically ill patient, invasive hemodynamic monitoring is often undertaken with a pulmonary artery catheter. The use of these devices is controversial.8 9 10 Obtain pressure measurements of the pulmonary circulation using a pulmonary artery flowdirected catheter. These catheters also permit cardiac output measurements using the thermodilution technique. If both cardiac output and pulmonary artery occlusive pressures are low, fluid challenge with reassessment of pressures and cardiac output is indicated. In the patient with an AMI, ventricular compliance may be reduced and filling pressures elevated. The precise level of pulmonary occlusive pressure needed to achieve optimal cardiac output will vary, but it is often 18 mm Hg, which is higher than normal and may vary depending on patient and pathological conditions. If hypotension or hypoperfusion persists after filling pressure is optimized, inotropic (dobutamine), vasopressor (dopamine or norepinephrine), or vasodilator (nitroprusside or nitroglycerin) therapy may be indicated. The use of these agents is outlined in the algorithm for acute pulmonary edema, hypotension, and shock (Part 7, Section 1) and is discussed in the related text.
Renal System
The bladder must be catheterized so that urine output can be
measured hourly and an accurate volume can be established (output
includes suctioned gastric secretions, diarrheal fluid, and vomitus as
well as urine). In the oliguric patient, measurement of
pulmonary artery occlusive pressures and cardiac output along
with evaluation of the urine sediment, electrolyte values, and
measurement of the fractional excretion of filtered sodium may be
helpful in differentiating prerenal from renal failure. Furosemide may
maintain urine output despite developing renal failure. Dopamine at low
doses (1 to 3 µg/kg per minute) does not improve splanchnic blood
flow or provide specific renal protection and is no longer indicated in
acute oliguric renal failure.31 32 33 34 35 36 Nephrotoxic drugs and
drugs eliminated via the kidneys should be used with caution and
monitored appropriately, and doses should be adjusted. Progressive
renal failure is indicated by a steadily rising serum urea nitrogen and
creatinine, usually with hyperkalemia, and
mortality and comorbidity are high in these patients, who often require
dialysis.
Central Nervous System
A healthy brain and a functional patient are the primary
goal of cardiopulmonary-cerebral resuscitation. Brain-oriented
intensive care is essential. Cessation of circulation for 10 seconds
results in a deficiency of oxygen supply to the brain that causes
unconsciousness. After 2 to 4 minutes, glucose and glycogen stores of
the brain are depleted, and after 4 to 5 minutes ATP is exhausted.
Autoregulation of cerebral blood flow is lost after extended hypoxemia
or hypercarbia, or both, and cerebral blood flow becomes dependent on
cerebral perfusion pressure. The cerebral perfusion pressure is equal
to mean arterial pressure minus intracranial pressure
(CPP=MAP-ICP). Following ROSC, after a brief initial period of
hyperemia, cerebral blood flow is reduced (the "no-reflow
phenomenon") as a result of microvascular dysfunction. This reduction
occurs even when cerebral perfusion pressure is normal. Any elevation
of intracranial pressure or reduction in systemic mean
arterial pressure may reduce cerebral perfusion pressure
and further compromise cerebral blood flow.
Therapy for the unresponsive patient should include measures to optimize cerebral perfusion pressure by maintaining a normal or slightly elevated mean arterial pressure and reducing intracranial pressure if it is increased. Because hyperthermia and seizures increase the oxygen requirements of the brain, normothermia should be maintained and seizure activity controlled with phenobarbital, phenytoin, or diazepam or barbiturate. The head should be elevated to approximately 30° and maintained in a midline position to increase cerebral venous drainage. Care should be observed during tracheal suctioning because of the increase in intracranial pressure during this procedure. Preoxygenation with 100% oxygen helps prevent hypoxemia during suctioning. Although there is exciting experimental data on preserving central nervous system function, no treatment is sufficiently established at present to warrant its routine use after resuscitation. Nonetheless, vigilant attention to the details of oxygenation and perfusion of the brain after resuscitation can significantly reduce the possibility of secondary neurological injury and maximize the chances of full neurological recovery.
Gastrointestinal System
A nasogastric tube should be inserted if bowel sounds are absent
and in those patients with a reduced level of consciousness who are
mechanically ventilated. Start enteric feeding as soon as possible. If
enteric feeding is not tolerated, administer histamine
H2-receptor blockers or sucralfate to
reduce the risk of stress ulceration and gastrointestinal bleeding.
| SIRS and Septic Shock |
|---|
|
|
|---|
The goal of hemodynamic management is normal tissue oxygen uptake. Initial management consists of volume replacement. Following volume replacement, an inotrope or vasopressin is usually required.41 42 43 Dobutamine and norepinephrine may be useful in severe septic shock.44 45 46 47 Improved outcome, however, has not been shown with the use of volume expansion and inotropic support. When sepsis is suspected, empirical antibiotic therapy is indicated and should be directed at common and usual organisms.
The use of glucocorticoid therapy in septic shock has been the subject of unresolved debates in critical care for almost half a century. The predominant controversies focus on the normal adrenal responses to sepsis, "normal" cortisol levels in the stressed state, exacerbation of active infectious processes, and significant metabolic derangements.
Relative hypoadrenalism occurs in septic shock even in the presence of normal and high cortisol levels. Methylprednisolone was found to have no mortality benefit and, in fact, in patients taking methylprednisolone there was a slight increase in mortality. No significant differences were found in the prevention of shock, the reversal of shock, or overall mortality. Patients treated with methylprednisolone experienced more deaths from secondary infection than the control group.48
Studies using lower, "supraphysiological" corticosteroid doses have been published.49 50 51 These studies have concluded that methylprednisolone shortens the pressor-dependent phase of shock and reduces the amount of organ system dysfunction. At present there is no evidence that corticosteroids improve survival rates.
Supraphysiological doses of corticosteroids may be beneficial for patients with persistent vasopressor-resistant shock maximally treated with broad-spectrum or organism-specific antimicrobial therapy (Class IIb).
In summary, care of the patient after resuscitation from cardiac arrest involves a careful assessment of the many organs subjected to an anoxic-hypoxic insult. Information in the patient with the postresuscitation syndrome is continuing to evolve as pathophysiological mechanisms of the SIRS and MODS are elucidated. The splanchnic circulation and gut are assuming increased importance for targeted therapy in long-term outcome and survival.6 Physicians should be skilled and knowledgeable in all aspects of care in these complicated survivors of cardiac arrest and shock syndromes.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
1.
Lafont A, Marwick TH, Chisolm GM, Van Lente F, Vaska
KJ, Whitlow PL. Decreased free radical scavengers with reperfusion
after coronary angioplasty in patients with acute myocardial
infarction. Am Heart J.. 1996;131:219223.
1.
Lonn E, Factor SM, Van Hoeven KH, Wen WH, Zhao M,
Dawood F, Liu P. Effects of oxygen free radicals and scavengers on the
cardiac extracellular collagen matrix during ischemia-reperfusion.
Can J Cardiol.. 1994;10:203213.
1.
Tan S, Yokoyama Y, Wang Z, Zhou F, Nielsen V, Murdoch
AD, Adams C, Parks DA. Hypoxia-reoxygenation is as damaging as
ischemia-reperfusion in the rat liver [see comments]. Crit Care
Med.. 1998;26:10891095.
1.
Zimmerman BJ, Granger DN. Mechanisms of reperfusion
injury. Am J Med Sci.. 1994;307:284292.
2.
Negrovsky VA. The second step in resuscitation: the
treatment of post- resuscitation disease. Resuscitation.. 1972;1:17.
3.
Homer-Vanniasinkam S, Crinnion JN, Gough MJ.
Post-ischaemic organ dysfunction: a review. Eur J Vasc Endovasc
Surg.. 1997;14:195203.
4.
Nielsen VG, Tan S, Baird MS, McCammon AT, Parks DA.
Gastric intramucosal pH and multiple organ injury: impact of
ischemia-reperfusion and xanthine oxidase. Crit Care Med.. 1996;248:13391344.
5.
Weinbroum AA, Hochhauser E, Rudick V, Kluger Y,
Sorkine P, Karchevsky E, Graf E, Boher P, Flaishon R, Fjodorov D, Niv
D, Vidne BA. Direct induction of acute lung and myocardial dysfunction
by liver ischemia and reperfusion. J Trauma.. 1997;43:627633; discussion 633635.
6.
Marik PE. Total splanchnic resuscitation, SIRS, and
MODS [editorial; comment]. Crit Care Med.. 1999;27:257258.
7.
Maynard N, Bihari D, Beale R, Smithies M, Baldock G,
Mason R, McColl I. Assessment of splanchnic oxygenation by gastric
tonometry in patients with acute circulatory failure [see comments].
JAMA.. 1993;270:12031210.
8.
Bernard GR, Sopko G, Cerra F, Demling R, Edmunds H,
Kaplan S, Kessler L, Masur H, Parsons P, Shure D, Webb C, Weidemann H,
Weinmann G, Williams D. Pulmonary artery catheterization and clinical
outcomes: National Heart, Lung, and Blood Institute and Food and Drug
Administration workshop report. JAMA.. 2000;283:25682572.
9.
Mimoz O, Rauss A, Rekik N, Brun-Buisson C, Lemaire F,
Brochard L. Pulmonary artery catheterization in critically ill
patients: a prospective analysis of outcome changes associated with
catheter-prompted changes in therapy [see comments]. Crit Care
Med.. 1994;22:573579.
10.
Vincent JL, Dhainaut JF, Perret C, Suter P. Is the
pulmonary artery catheter misused? A European view [see comments].
Crit Care Med.. 1998;26:12831287.
11.
Doglio GR, Pusajo JF, Egurrola MA, Bonfigli GC, Parra
C, Vetere L, Hernandez MS, Fernandez S, Palizas F, Gutierrez G. Gastric
mucosal pH as a prognostic index of mortality in critically ill
patients [see comments]. Crit Care Med.. 1991;19:10371040.
11.
Gutierrez G, Palizas F, Doglio G, Wainsztein N, Gallesio
A, Pacin J, Dubin A, Schiavi E, Jorge M, Pusajo J, et al. Gastric
intramucosal pH as a therapeutic index of tissue oxygenation in
critically ill patients [see comments]. Lancet.. 1992;339:195199.
12.
Gys T, Hubens A, Neels H, Lauwers LF, Peeters R.
Prognostic value of gastric intramural pH in surgical intensive care
patients. Crit Care Med.. 1988;16:12221224.
13.
Nielsen VG, Tan S, Baird MS, McCammon AT, Parks DA.
Gastric intramucosal pH and multiple organ injury: impact of
ischemia-reperfusion and xanthine oxidase. Crit Care Med.. 1996;24:13391344.
14.
Spaulding CM, Joly LM, Rosenberg A, Monchi M, Weber SN,
Dhainaut JF, Carli P. Immediate coronary angiography in
survivors of out-of-hospital cardiac arrest [see comments].
N Engl J Med. 1997;336:16291633.
15.
Holzer M, Behringer W, Schorkhuber W, Zeiner A, Sterz
F, Laggner AN, Frass M, Siostrozonek P, Ratheiser K, Kaff A,
Hypothermia for Cardiac Arrest (HACA) Study Group. Mild hypothermia and
outcome after CPR. Acta Anaesthesiol Scand Suppl. 1997;111:5558.
16.
Leonov Y, Sterz F, Safar P, Radovsky A, Oku K,
Tisherman S, Stezoski SW. Mild cerebral hypothermia during and after
cardiac arrest improves neurologic outcome in dogs. J Cereb
Blood Flow Metab. 1990;10:5770.
17.
Marion DW, Leonov Y, Ginsberg M, Katz LM, Kochanek PM,
Lechleuthner A, Nemoto EM, Obrist W, Safar P, Sterz F, Tisherman SA,
White RJ, Xiao F, Zar H. Resuscitative hypothermia. Crit Care
Med. 1996;24:S81S89.
18.
Schwab S, Schwarz S, Spranger M, Keller E, Bertram M,
Hacke W. Moderate hypothermia in the treatment of patients with severe
middle cerebral artery infarction [see comments]. Stroke. 1998;29:24612466.
19.
Steinman AM. Cardiopulmonary resuscitation and
hypothermia. Circulation. 1986;74(suppl IV):IV-29IV-32.
20.
Sterz F, Safar P, Tisherman S, Radovsky A, Kuboyama K,
Oku K. Mild hypothermic cardiopulmonary resuscitation improves
outcome after prolonged cardiac arrest in dogs [see comments].
Crit Care Med. 1991;19:379389.
21.
Sterz F, Zeiner A, Kurkciyan I, Janata K, Mullner M,
Domanovits H, Safar P. Mild resuscitative hypothermia and outcome after
cardiopulmonary resuscitation. J Neurosurg
Anesthesiol. 1996;8:8896.
22.
Rosomoff HL, Holaday DA. Cerebral blood flow and
cerebral oxygen consumption during hypothermia. Am J
Physiol. 1954;179:8588.
23.
Ausina A, Baguena M, Nadal M, Manrique S, Ferrer A,
Sahuquillo J, Garnacho A. Cerebral hemodynamic changes
during sustained hypocapnia in severe head injury: can
hyperventilation cause cerebral ischemia? Acta Neurochir
Suppl. 1998;71:14.
24.
Diringer MN, Yundt K, Videen TO, Adams RE, Zazulia AR,
Deibert E, Aiyagari V, Dacey RG Jr, Grubb RL Jr, Powers WJ. No
reduction in cerebral metabolism as a result of early
moderate hyperventilation following severe traumatic brain injury.
J Neurosurg. 2000;92:713.
25.
Yundt KD, Diringer MN. The use of hyperventilation and
its impact on cerebral ischemia in the treatment of traumatic
brain injury. Crit Care Clin. 1997;13:163184.
26.
Safar P, Xiao F, Radovsky A, Tanigawa K, Ebmeyer U,
Bircher N, Alexander H, Stezoski SW. Improved cerebral resuscitation
from cardiac arrest in dogs with mild hypothermia plus blood flow
promotion. Stroke. 1996;27:105113.
27.
Gottfried SB, Rossi A, Milic-Emili J. Dynamic
hyperinflation, intrinsic PEEP, and the mechanically ventilated
patient. Crit Care Digest. 1986;5:3033.
28.
Ligas JR, Mosiehi F, Epstein MAF. Occult positive
end-expiratory pressure with different types of mechanical ventilators.
J Crit Care. 1990;52:95100.
29.
Dybvik T, Strand T, Steen PA. Buffer therapy during
out-of-hospital cardiopulmonary resuscitation [see comments].
Resuscitation. 1995;29:8995.
30.
Kette F, Weil MH, Gazmuri RJ. Buffer solutions may
compromise cardiac resuscitation by reducing coronary perfusion
pressure [published erratum appears in JAMA. 1991;266:3286] [see comments]. JAMA. 1991;266:21212126.
31.
Bersten AD, Holt AW. Vasoactive drugs and the
importance of renal perfusion pressure. New Horiz. 1995;3:650661.
32.
Marik PE. Low-dose dopamine in critically ill oliguric
patients: the influence of the renin-angiotensin system.
Heart Lung. 1993;22:171175.
33.
Marik PE, Iglesias J, NORASEPT II Study Investigators.
Low-dose dopamine does not prevent acute renal failure in patients with
septic shock and oliguria. Am J Med. 1999;107:387390.
34.
Chertow GM, Sayegh MH, Allgren RL, Lazarus JM,
Auriculin Anaritide Acute Renal Failure Study Group. Is the
administration of dopamine associated with adverse or favorable
outcomes in acute renal failure? Am J Med. 1996;101:4953.
35.
Denton MD, Chertow GM, Brady HR. Renal-dose dopamine
for the treatment of acute renal failure: scientific rationale,
experimental studies and clinical trials. Kidney Int. 1996;50:414.
36.
Thompson BT, Cockrill BA. Renal-dose dopamine: a siren
song? Lancet. 1994;344:78.
37.
Baue AE, Durham R, Faist E. Systemic inflammatory
response syndrome (SIRS), multiple organ dysfunction syndrome (MODS),
multiple organ failure (MOF): are we winning the battle? [see
comments]. Shock. 1998;10:7989.
38.
Goris RJ. MODS/SIRS: result of an overwhelming
inflammatory response? [see comments]. World J Surg. 1996;20:418421.
39.
Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis
CS, Wenzel RP. The natural history of the systemic inflammatory
response syndrome (SIRS): a prospective study [see comments].
JAMA. 1995;273:117123.
40.
Muckart DJ, Bhagwanjee S. American College of
Chest Physicians/Society of Critical Care Medicine Consensus Conference
definitions of the systemic inflammatory response syndrome and allied
disorders in relation to critically injured patients [see comments].
Crit Care Med. 1997;25:17891795.
41.
Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S,
DAlessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes
to the vasodilation of septic shock [see comments].
Circulation. 1997;95:11221125.
42.
Malay MB, Ashton RC Jr, Landry DW, Townsend RN.
Low-dose vasopressin in the treatment of vasodilatory septic shock.
J Trauma. 1999;47:699703; discussion 703705.
43.
Reid IA. Role of vasopressin deficiency in the
vasodilation of septic shock [editorial; comment].
Circulation. 1997;95:11081110.
44.
Rhodes A, Lamb FJ, Malagon I, Newman PJ, Grounds RM,
Bennett ED. A prospective study of the use of a dobutamine
stress test to identify outcome in patients with sepsis, severe sepsis,
or septic shock [see comments]. Crit Care Med. 1999;27:23612366.
45.
Lherm T, Troche G, Rossignol M, Bordes P, Zazzo JF.
Renal effects of low-dose dopamine in patients with sepsis syndrome or
septic shock treated with catecholamines. Intensive
Care Med. 1996;22:213219.
46.
Marik PE, Mohedin M. The contrasting effects of
dopamine and norepinephrine on systemic and splanchnic
oxygen utilization in hyperdynamic sepsis. JAMA. 1994;272:13541357.
47.
Duke GJ, Briedis JH, Weaver RA. Renal support in
critically ill patients: low-dose dopamine or low-dose dobutamine?
[see comments]. Crit Care Med.. 1994;22:19191925.
48.
Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA,
Balk RA. A controlled clinical trial of high-dose methylprednisolone in
the treatment of severe sepsis and septic shock. N Engl
J Med. 1987;317:653658.
49.
Briegel J, Forst H, Haller M, Schelling G, Kilger E,
Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K.
Stress doses of hydrocortisone reverse hyperdynamic septic shock: a
prospective, randomized, double-blind, single-center study [see
comments]. Crit Care Med.. 1999;27:723732.
50.
Schelling G, Stoll C, Kapfhammer HP, Rothenhausler HB,
Krauseneck T, Durst K, Haller M, Briegel J. The effect of stress doses
of hydrocortisone during septic shock on posttraumatic stress disorder
and health-related quality of life in survivors. Crit Care
Med. 1999;27:26782683.
51.
Bollaert PE, Charpentier C, Levy B, Debouverie M,
Audibert G, Larcan A. Reversal of late septic shock with
supraphysiologic doses of hydrocortisone [see comments]. Crit
Care Med. 1998;26:645650.
This article has been cited by other articles:
![]()
![]()

![]()
![]()
![]()
C. Adrie, M. Adib-Conquy, I. Laurent, M. Monchi, C. Vinsonneau, C. Fitting, F. Fraisse, A. T. Dinh-Xuan, P. Carli, C. Spaulding, et al.
Successful Cardiopulmonary Resuscitation After Cardiac Arrest as a "Sepsis-Like" Syndrome
Circulation,
July 30, 2002;
106(5):
562 - 568.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
E. Prifti, V. Vanini, M. Bonacchi, G. Frati, M. Bernabei, G. Giunti, A. Crucean, S. Vincenzo Luisi, and B. Murzi
Repair of congenital malformations of the mitral valve: early and midterm results
Ann. Thorac. Surg.,
February 1, 2002;
73(2):
614 - 621.
[Abstract]
[Full Text]
[PDF]
![]()
This Article ![]()
![]()
Extract
![]()
Alert me when this article is cited
![]()
Alert me if a correction is posted
![]()
Services ![]()
![]()
Email this article to a friend
![]()
Similar articles in this journal
![]()
Similar articles in PubMed
![]()
Alert me to new issues of the journal
![]()
Download to citation manager
![]()
Request Permissions ![]()
Citing Articles ![]()
![]()
Citing Articles via HighWire
![]()
Citing Articles via Google Scholar
![]()
Google Scholar ![]()
![]()
Search for Related Content
![]()
PubMed ![]()
![]()
PubMed Citation
![]()
Related Collections ![]()
![]()
AHA Statements and Guidelines
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |